The list of potential health benefits from GLP-1 is only getting longer. Meanwhile, the heads of Commure, Augmedix share details about an acquisition.
Good afternoon! The list of potential health benefits from a booming class of weight loss and diabetes drugs is only growing longer.'s older, once-daily GLP-1 for diabetes and obesity called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains.found that semaglutide – the active ingredient in Novo Nordisk's weight loss injection Wegovy and diabetes counterpart Ozempic – may also help people quit smoking.
Novo Nordisk is planning a study with a secondary goal of seeing whether semaglutide and other treatments can change daily alcohol consumption, according to the U.S. government's clinical trials. The main goal of mid-stage trial is measuring the drugs' impact on liver scarring in patients with alcoholic-relate liver disease.Commure offers a suite of solutions, including an AI scribe and a revenue cycle service, designed to help lessen clinicians' administrative workloads.
On July 19, Commure agreed to take Augmedix private in an all-cash deal. Commure will purchase all of Augmedix's outstanding common stock at a total equity value of about $139 million, according toCNBC caught up with Commure CEO Tanay Tandon and Augmedix CEO Manny Krakaris on Monday to learn a little more about the acquisition and what it means for both organizations.
"You have to have documentation that covers the entire journey. It doesn't just stop when they leave the , and then restart again when they're admitted into the hospital as an inpatient," Krakaris said."Today, there's a whole massive, labor intensive step to try to bridge those two worlds." "It's kind of beneath the surface, it's kind of like an iceberg, but that's where the value creation is," he said."It's not something that's very visible from the application itself."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Healthy bees, healthy planet: The impact of balanced diets on honeybee coloniesA new study from the Hebrew University of Jerusalem has revealed that a balanced diet is essential for the optimal health and task performance of honeybees, a key species for pollination and ecosystem stability. The study, led by Prof. Sharoni Shafir from the Robert H.
Read more »
Healthy Returns: The first round of Medicare drug price negotiations is nearing an endThe first round of Biden’s Medicare drug price negotiations is nearly finished. Meanwhile, Abridge, Epic and Mayo Clinic are bringing AI tools to nurses.
Read more »
Healthy Returns: The first round of Medicare drug price negotiations is nearing an endThe first round of Biden’s Medicare drug price negotiations is nearly finished. Meanwhile, Abridge, Epic and Mayo Clinic are bringing AI tools to nurses.
Read more »
Healthy Returns: Diabetes drug Ozempic may lower dementia risk, nicotine useNew study suggests that Novo Nordisk’s Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group’s cyberattack woes…
Read more »
Healthy Returns: Diabetes drug Ozempic may lower dementia risk, nicotine useNew study suggests that Novo Nordisk’s Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group’s cyberattack woes…
Read more »
Healthy Returns: Drugmakers are racing to develop more convenient weight loss pillsNovo Nordisk, Eli Lilly and Pfizer are developing weight loss pills. Meanwhile, digital health funding shows ‘measured momentum’ this year, a report…
Read more »